114 Western Avenue
About Shepherd Therapeutics
The mission of Shepherd is to cure rare cancers. Founded by a rare cancer patient, Shepherd is a biotechnology company relentlessly focused on using deep disease understanding, development expertise, and an unwavering commitment to save people dying of neglected rare cancers. Shepherd is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.
Founders: Eugene Williams and David Hysong
Founder and CEO: David Hysong
CSO: Johanne Kaplan
CMO and CBO: Abby V. Reiner
COO: Elizabeth Hostetter
CRO: Jamie Dempsey Barber
CCO: Lacie Randall
CDO: William Siders
5 articles about Shepherd Therapeutics
SHEPHERD Therapeutics Presents First Public Data at 2021 ESMO Congress Highlighting Ability of DELVE Computational Approach to Optimize Therapeutic Selection for Cancer Patients
SHEPHERD Therapeutics, a company dedicated to catalyzing lifesaving treatments for cancer patients, is pleased to present an e-poster of results from a computational approach to optimizing therapeutic selection for cancer patients using the Company’s proprietary precision-oncology DELVE platform, at the European Society for Medical Oncology Virtual Congress 2021.
SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development and Commercialization of Oncology Therapeutics For Rare Cancers
SHEPHERD Therapeutics , a company dedicated to catalyzing lifesaving treatments for rare cancer patients, and Oncoheroes Biosciences , a biotech company focused on advancing new therapies for childhood cancer, today announced they have entered into a partnership to collaborate in the discovery, development and commercialization of innovative drug products
5/1/2018Biopharmaceutical companies are focusing their drugs for smaller and smaller and more clearly delineated patient populations. No longer is a drug for lung cancer or even non-small cell lung cancer, but a much smaller segment.
There are many unusual things about Shepherd Therapeutics, but one of them is its origin.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.